PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Zimmerman T. Clin Neuropharmacol. Apr 1991; 14(2): 165-9 Pubmed [10968]
Zimmermann AE. Clin Infect Dis. Jan 2006; 42(2): 283-90 Pubmed [5687]
Zini R. Int J Clin Pharmacol Ther Toxicol. Feb 1991; 29(2): 64-6 Pubmed [10049]
Zink M. Pharmacopsychiatry. May 2006; 39(3): 109-11 Pubmed [10487]
Zirkle GA, King PD, McAtee OB, Van Dyke R. Effects of chlorpromazine and alcohol on coordination and judgment. JAMA (1959) 171, 1496-9 [817]
Zirwas MJ. Dermatitis. Dec 2006; 17(4): 208-10 Pubmed [8917]
Zisook S. Biol Psychiatry. Feb 2006; 59(3): 203-10 Pubmed [8405]
Zitelli BJ. Clin Pediatr (Phila). Mar 1987; 26(3): 117-9 Pubmed [5863]
Zitron E. Circulation. Feb 2005; 111(7): 835-8 Pubmed [11682]
Zo'o M. Pediatr Radiol. Nov 2011; 41(11): 1393-400 Pubmed, Volltext, Springer [4918]
Zoccali et al. (2007) J Clin Psychopharmacol 93:109-116 [1144]
Zoccali R. Pharmacol Res. Oct 2003; 48(4): 411-4 Pubmed [2545]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics, Novembet 2001 [2504]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics. November 2001 [2078]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., November 2001 [1646]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., Novembet 2001 [945]
Zoleptil (Zotepine). Knoll Limited. Summary of product characteristics, November 2001 [2515]
Zomorodi K. Clin Pharmacol Drug Dev. Apr 2021; 10(4): 404-413 Pubmed, Volltext, DOI [10296]
Zong J. J Int AIDS Soc. Nov 2014; 17(4 Suppl 3): 19584 Pubmed, Volltext, DOI [6639]
Zor M. Int Urogynecol J. Jul 2015; 26(7): 959-66 Pubmed [8295]
Zoungas S. Diabetes Obes Metab. Apr 2020; 22 Suppl 2: 5-11 Pubmed [11786]
Zubieta, Demitrack. J Clin Pharmacol (1991) 11, 327-328 [1336]
Zubillaga I. Endocrinol Diabetes Nutr. Jan 2017; 64(6): 338-339 Pubmed [6373]
Zuchora B. Eur Neuropsychopharmacol. Jan 2005; 15(1): 85-93 Pubmed [9712]
Zullino DF. Br J Clin Pharmacol. Jan 2005; 59(1): 118-9; author reply 119 Pubmed [10815]
Zullino DF. Drugs Today (Barc). Jul 2004; 40(7): 603-19 Pubmed [4174]
Zullino DF. Int Clin Psychopharmacol. May 2002; 17(3): 141-3 Pubmed [1193]
Zumoff B. JAMA. May 1977; 237(18): 1960-1 Pubmed [792]
Zung S. Braz J Psychiatry. Mar 2006; 28(1): 84-5 Pubmed [8639]
Zuo R. Drug Metab Dispos. Feb 2017; 45(2): 198-207 Pubmed, Volltext, DOI [7586]
Zuo XC. Drug Metab Pharmacokinet. Jan 2014; 29(4): 305-11 Pubmed [10194]
Zusammenfassung der zur Zulassung eingereichten Klinischen Studien: ZHANG, J: FDA Clinical Review of Olanzapine Pamoate Depot in the Treatment of Schizophrenie: http://www.fda.gov/ohrms/dockets/AC/08/slides/2008-4338s1-01-FDA-Zhang_files/frames.htm [3029]
Zwanzger P. J Clin Psychiatry. Mar 2001; 62(3): 208-9 Pubmed [1672]
Zweers-Zeilmaker WM. Xenobiotica. Aug 1997; 27(8): 769-80 Pubmed [4510]
Zylber-Katz E. Ann Pharmacother. Feb 1995; 29(2): 127-31 Pubmed [6005]
Zylber-Katz E. Drug Intell Clin Pharm. Jun 1988; 22(6): 504-5 Pubmed [5573]